(Source: Spring Bank Pharmaceuticals Inc) HOPKINTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and cancer, today announced that it has begun dosing the first cohort of patients in the ACHIEVE global Phase 2 clinical program evaluating SB 9200 in immuno-active, treatment-naïve HBV patients without cirrhosis. SB 9200 is the Company's novel small molecule nucleic acid hybrid (SMNH) compound being developed as both monotherapy and combination therapy for the treatment of Hepatitis B (HBV) and other viral diseases....
↧